BMO Capital Maintains Hold Rating on HealthEquity Amid Strong EBITDA Growth and Valuation Concerns

, an analyst from BMO Capital, has initiated a new Hold rating on Healthequity (HQY).

BMO Capital’s rating is based on a combination of factors that influence Healthequity’s current and future financial performance. The company has experienced strong EBITDA growth due to increased custodial cash yields, which are expected to continue providing a positive impact for the next two years. However, after this period, growth is anticipated to moderate as the benefits from these yields diminish.
BMO Capital acknowledges the positive outlook for HealthEquity’s HSA account growth, supported by new legislation and potential cost reductions through AI. Despite these opportunities, the current valuation of the stock at 16x NTM EBITDA suggests that shares are fully valued, especially as the economic environment shifts towards lower interest rates. Therefore, while there are growth prospects, the potential for significant upside appears limited, justifying the Hold rating.